Silence Therapeutics plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Silence Therapeutics plc (SLNCF) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -8.89% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-05
- Silence Therapeutics plc effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was -8.89%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2025-12-31 | -8.89% 10-K · filed 2026-03-05 |